Clinical trials: Solid Tumours
Adult Intracranial Tumor, Adult Solid Tumor
A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain
This will be a randomized blinded clinical trial. Patients will be randomized to receive either a remifentanil or dexmedetomidine infusion for general anesthesia.
- Trial name
- RemivsDex (NCT01269918)
- Testing
- Remifentanil, Dexmedetomidine
- Where
- 2 sites in United States
- Volunteers
- 142 people
- Sponsor
- The Cleveland Clinic
Small Cell Lung Cancer, Gastric Adenocarcinoma
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
The purpose of this signal seeking study is to determine whether treatment with PDR001 and LAG525 demonstrates sufficient efficacy in advanced malignancies to warrant further study.
- Conditions
- Small Cell Lung Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Castration Resistant Prostate Adenocarcinoma
- Trial name
- NCT03365791
- Testing
- PDR001, LAG525
- Where
- 20 sites in United States
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Non-squamous, Non-Small Cell Lung Cancer
Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.
Characteristics of patients with Neuregulin-1 (NRG1) gene fusion-positive solid tumors treated with afatinib, and characteristics of those treated with another systemic therapy.
- Trial name
- NCT04750824
- Testing
- Afatinib, other systemic therapy
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Boehringer Ingelheim
Cancer: Solid Tumors
An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors
The purpose of this study is to determine the maximum tolerable dose (MTD) and the related effects of E7080 administered to patients with solid tumors that are resistant to approved existing anti-tumor therapies, or for which no…
- Trial name
- NCT00280397
- Testing
- E7080
- Where
- Japan
- Volunteers
- 27 people
- Sponsor
- Eisai Inc.
Metastatic Cancer, Solid Tumor
Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
This is the first study to test Sym022 in humans. The primary purpose of this study is to see if Sym022 is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas…
- Conditions
- Metastatic Cancer, Solid Tumor, Lymphoma
- Trial name
- NCT03489369
- Testing
- Sym022
- Where
- 3 sites in United States, Canada
- Volunteers
- 15 people
- Sponsor
- Symphogen A/S
Advanced Malignancies, Advanced Cancer
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
The purpose of this study was to evaluate the safety, tolerability, and clinical response of ASP7517, and determine the Recommended Phase 2 Dose (RP2D) and/or the Maximum Tolerated Dose (MTD) of ASP7517 when administered as a…
- Trial name
- NCT04837196
- Testing
- ASP7517, Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Metastases, Neoplasm, Carcinoma, Non-small Cell Lung
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Study I3G-MC-JGCB (JGCB) is a multicenter, nonrandomized, open-label, dose-escalation Phase 1b study of LY2584702 in combination with either erlotinib or everolimus.
- Conditions
- Metastases, Neoplasm, Carcinoma, Non-small Cell Lung, Renal Cell Carcinoma, Neuroendocrine Tumors
- Trial name
- NCT01115803
- Testing
- LY2584702, Erlotinib, Everolimus
- Where
- 3 sites in United States, France
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain.
- Conditions
- CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation
- Trial name
- NCT03994796
- Testing
- Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib
- Where
- 435 sites in United States
- Volunteers
- 50 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Ovarian Cancer
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
This was a Phase 1, open-label, nonrandomized, multicenter study of durvalumab and tremelimumab in subjects with advanced cancers who were not eligible for, declined, or failed standard treatment.
- Conditions
- Breast Cancer, Ovarian Cancer, Colorectal Cancer, Cervical Cancer
- Trial name
- NCT01975831
- Testing
- Durvalumab, Tremelimumab
- Where
- 6 sites in United States
- Volunteers
- 104 people
- Sponsor
- Ludwig Institute for Cancer Research
Cancer, Small Cell Lung Cancer
A Phase I/II Study of Ganetespib in Combination With Doxorubicin
This is a Phase I/safety dose expansion study of the combination of the drug ganetespib and doxorubicin in patients with advanced solid tumors.
- Trial name
- NCT02261805
- Testing
- Ganetespib, Doxorubicin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Georgetown University
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)
This phase II MATCH treatment trial tests how well palbociclib (PD-0332991) works in treating patients with cancer that has certain genetic changes. Palbociclib (PD-0332991) is in a class of medications called kinase inhibitors.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06390839
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD) and to explore the safety and anti-tumor activity of E7389 in combination with carboplatin in patients with advanced solid tumors.
- Trial name
- NCT00268905
- Testing
- E7389 + carboplatin AUC 5, E7389 + carboplatin AUC 6, E7389+carboplatin AUC 6
- Where
- 11 sites in United States, Austria and 1 more
- Volunteers
- 64 people
- Sponsor
- Eisai Inc.
Relapsed or Refractory Solid Tumors, Nonsmall Cell Lung Cancer
Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer
For the phase I component of the trial a classic 3 + 3 dose escalation design will be utilized, with a fixed dose of pembrolizumab and an escalating dose of the lenalidomide.
- Trial name
- NCT02963610
- Testing
- Lenalidomide, Pembrolizumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Fox Chase Cancer Center
Advanced Solid Tumors, Solid Tumors
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
This will be a Phase 1, open label, 2-sequence, crossover study to establish the BE of the current commercial formulation (Generation 3.1 talazoparib capsules) to the proposed talazoparib liquid-filled soft gelatin capsule (soft…
- Conditions
- Advanced Solid Tumors, Solid Tumors, Ovarian Cancer, Breast Cancer
- Trial name
- NCT04672460
- Testing
- TALZENNA capsule, Talazoparib soft gel capsule
- Where
- 31 sites in United States, Australia
- Volunteers
- 73 people
- Sponsor
- Pfizer
Advanced Malignancies
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
The primary objective is to assess the safety and tolerability of Toripalimab in subjects with various advanced malignancies and to evaluate the recommended Phase 2 dose.
- Trial name
- NCT03474640
- Testing
- Part A, Part B
- Where
- 14 sites in United States
- Volunteers
- 184 people
- Sponsor
- TopAlliance Biosciences
Solid Tumors, Lymphoma
Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)
The purpose of this study is to identify a maximum tolerated dose (MTD) or maximum administered dose (MAD) of ulevostinag alone and of ulevostinag in combination with pembrolizumab in participants with advanced/metastatic solid…
- Trial name
- NCT03010176
- Testing
- Ulevostinag, Pembrolizumab
- Where
- 19 sites in United States, France and 3 more
- Volunteers
- 156 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumors
AZD1775 for Advanced Solid Tumors
BACKGROUND: Wee1 is a tyrosine kinase involved in the phosphorylation and inactivation of cyclin-dependent kinase 1 (CDK1/CDC2)-bound cyclin B, resulting in G2 cell cycle arrest in response to deoxyribonucleic acid (DNA) damage…
- Trial name
- NCT01748825
- Testing
- MK-1775 (AZD1775)
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor
Study of RP-3500, Camonsertib, in Advanced Solid Tumors
The primary purpose of this study is to define the maximum tolerated dose (MTD) and determine a recommended Phase 2 dose (RP2D) and schedule of orally-administered RP-3500 (camonsertib) alone or in combination with talazoparib, a…
- Trial name
- TRESR (NCT04497116)
- Testing
- RP-3500 (camonsertib), Talazoparib, Gemcitabine Injection
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 276 people
- Sponsor
- Repare Therapeutics
Locally Advanced or Metastatic Solid Tumors
A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)
This study will investigate the safety and tolerability of combination therapy with MK-2206 and AZD6244 (selumetinib) and determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RPTD) for this drug combination in…
- Trial name
- NCT01021748
- Testing
- MK-2206, AZD6244
- Volunteers
- 63 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer, Pancreatic Cancer
High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies
This is a multicenter, single arm, 3-cohort, open-label trial of high dose Vitamin C intravenous infusion in subjects with solid tumor malignancies who are eligible for resection (cohort A) or with extended RAS (e.g.KRAS or NRAS)…
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT03146962
- Testing
- Vitamin C
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Weill Medical College of Cornell University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.